Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Bansback

Showing results (41-50 of 202) with videos related to

Pageof 21
Sort By:
Chest|May 6, 2015
The effect of OSA on work disability and work-related injuriesA J Marcus Hirsch Allen, Nick Bansback, Najib T Ayas
Vox Sanguinis|July 20, 2023
What influences decisions to donate plasma? A rapid review of the literatureMary Berger, Adam Easterbrook, Kelly Holloway, et al.
Best Practice & Research. Clinical Rheumatology|January 18, 2023
Personalized medicine in rheumatoid arthritis: Combining biomarkers and patient preferences to guide therapeutic decisionsJocelyn Thomas, Nick Bansback, Claire Barber, et al.
Best Practice & Research. Clinical Rheumatology|December 11, 2012
An update on the measurement of productivity losses due to rheumatoid diseasesWei Zhang, Judy A Chiu, Nick Bansback, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2013
Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect informationMohsen Sadatsafavi, Nick Bansback, Zafar Zafari, et al.
Arthritis Care & Research|October 23, 2025
​Did a Non-Medical Biosimilar Switching Policy Cause an Increase in Non-Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?HaoHung Dang, Sandra Blitz, Nick Bansback, et al.
Clinical Rheumatology|March 2, 2011
Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritisCarlo A Marra, Nick Bansback, Aslam H Anis, et al.
Journal of Clinical Epidemiology|September 1, 2024
Stakeholder-informed positivity thresholds for disease markers and risk scores: a methodological framework and an application in obstructive lung diseaseMohsen Sadatsafavi, Amir Khakban, Tima Mohammadi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitisDean A Regier, Nick Bansback, Anne Dar Santos, et al.
BMC Medical Research Methodology|January 13, 2021
When does the use of individual patient data in network meta-analysis make a difference? A simulation studySteve Kanters, Mohammad Ehsanul Karim, Kristian Thorlund, et al.
Pageof 21

Showing results (41-50 of 202) with videos related to

Sort By:
Pageof 21
Chest|May 6, 2015
The effect of OSA on work disability and work-related injuriesA J Marcus Hirsch Allen, Nick Bansback, Najib T Ayas
Vox Sanguinis|July 20, 2023
What influences decisions to donate plasma? A rapid review of the literatureMary Berger, Adam Easterbrook, Kelly Holloway, et al.
Best Practice & Research. Clinical Rheumatology|January 18, 2023
Personalized medicine in rheumatoid arthritis: Combining biomarkers and patient preferences to guide therapeutic decisionsJocelyn Thomas, Nick Bansback, Claire Barber, et al.
Best Practice & Research. Clinical Rheumatology|December 11, 2012
An update on the measurement of productivity losses due to rheumatoid diseasesWei Zhang, Judy A Chiu, Nick Bansback, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2013
Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect informationMohsen Sadatsafavi, Nick Bansback, Zafar Zafari, et al.
Arthritis Care & Research|October 23, 2025
​Did a Non-Medical Biosimilar Switching Policy Cause an Increase in Non-Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?HaoHung Dang, Sandra Blitz, Nick Bansback, et al.
Clinical Rheumatology|March 2, 2011
Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritisCarlo A Marra, Nick Bansback, Aslam H Anis, et al.
Journal of Clinical Epidemiology|September 1, 2024
Stakeholder-informed positivity thresholds for disease markers and risk scores: a methodological framework and an application in obstructive lung diseaseMohsen Sadatsafavi, Amir Khakban, Tima Mohammadi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitisDean A Regier, Nick Bansback, Anne Dar Santos, et al.
BMC Medical Research Methodology|January 13, 2021
When does the use of individual patient data in network meta-analysis make a difference? A simulation studySteve Kanters, Mohammad Ehsanul Karim, Kristian Thorlund, et al.
Pageof 21